Questionnaire

1. Abnormalities that give rise to the wide diversity of clinical PsO phenotypes can be:

2. A common symptom affecting 60-90% of patients with PsO is:

3. Overall, the impact of PsO on quality of life is comparable to that of other serious diseases such as:

4. The most prevalent comorbidity/ies associated with PsO is/are:

5. Among criteria that can be used to define PsO severity as mild are:

6. Mild-to-moderate PsO is defined by South African criteria as:

7. Although the main goal of treatment is to achieve complete skin clearance, holistic disease management should encompass challenging body areas,
patient-reported outcomes and comorbidities:

8. The class of biologics to which IXE belongs is:

9. Patients with PsO who achieve completely clear skin upon treatment are more likely to report better quality-of-life outcomes:

10. Inhibition of IL-17A reduces:

11. Attributes of IXE for the treatment of moderate-to-severe PsO include early, complete and sustained skin clearance, with an established safety and
tolerability profile:

12. Data arising from head-to-head trials demonstrate that, in terms of complete skin clearance in patients with PsO, IXE is more efficacious than:

13. Relative to other biologics, real-world evidence arising from the PSoHO study demonstrated a higher proportion of patients treated with IL-17A inhibitors achieving complete skin clearance (PASI 100), including challenging body areas, at:

14. A significantly increased risk for the development of PsA is associated with the presence of:

15. Regarding the safety and tolerability of IXE: